Canton Strategic Holdings (CNTN) EPS (Weighted Average and Diluted) (2022 - 2026)
Canton Strategic Holdings posted quarterly EPS (Weighted Average and Diluted) of -$0.23 for Q1 2026, up 76.77% year-on-year from -$0.13 in Q1 2025, and down 142.59% on a QoQ basis from $0.54 in Q4 2025.
Canton Strategic Holdings (CNTN) has 5 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.23 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 76.77% year-over-year to -$0.23; the trailing twelve-month figure through Mar 2026 stood at -$0.67 (up 91.5% YoY), and the FY2025 full-year result was -$1.12, up 88.1% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.23, down from $0.54 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $68.48 in Q4 2023 and bottomed at -$52.06 in Q2 2023.
- The 5-year median for EPS (Weighted Average and Diluted) is -$1.51 (2024), against an average of -$3.63.
- Peak annual rise in EPS (Weighted Average and Diluted) reached 477.92% in 2023, while the deepest fall reached 37285.71% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$18.12 in 2022, then surged by 477.92% to $68.48 in 2023, then sank by 102.95% to -$2.02 in 2024, then soared by 126.73% to $0.54 in 2025, then tumbled by 142.59% to -$0.23 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.23 (Q1 2026), $0.54 (Q4 2025), and -$0.34 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Canton Strategic Holdings | 643.89 Mn | 602.36 Mn | - | -0.23 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.23 |
| Dec 31, 2025 | 0.54 |
| Sep 30, 2025 | -0.34 |
| Jun 30, 2025 | -0.64 |
| Mar 31, 2025 | -0.99 |
| Dec 31, 2024 | -2.02 |
| Sep 30, 2024 | -2.45 |
| Jun 30, 2024 | -2.42 |
| Mar 31, 2024 | -2.55 |
| Dec 31, 2023 | 68.48 |
| Sep 30, 2023 | -39.42 |
| Jun 30, 2023 | -52.06 |
| Mar 31, 2023 | -5.84 |
| Dec 31, 2022 | -18.12 |
| Sep 30, 2022 | -0.18 |
| Jun 30, 2022 | 0.14 |